THE ADVANCE OF MARKERS FOR THYROID NEOPLASM_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XUE Gang ¹

Department of General Surgery, Chengdu Army General Hospital, Chengdu 610083;

Corresponding author：

Keywords：

Thyroid neoplasm Marker Diagnosis Prognosis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the markers which contribute to diagnosis and prognosis of thyroid neoplasm.
Methods The references about thyroid markers in recent years were reviewed.
Results CD26 and galectin-3 could be regarded as a simple, potent markers to differentiate thyroid carcinoma in preoperative diagnosis, CD97 was a specific marker for undifferentiated thyroid carcinoma and its metastasis, CD15 and telomerase could be used in fine-needle aspirate biopsy (FNAB) of thyroid mass, and to improve its diagnostic evaluation, RET/PTC was mainly expressed in thyroid medullary carcinoma, oncofetal fibronectin (oncFN) was specific to papillary and anaplastic carcinoma, thyroid peroxidase was used to identify benign and malignant thyroid tumor.
Conclusion Although there are a lot of markers for thyroid neoplasm, but there is no marker which are completely specific to certain histotype of thyroid neoplasm at present.

Citation： XUE Gang,YAO Zhenxiang.. THE ADVANCE OF MARKERS FOR THYROID NEOPLASM. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2000, 7(5): 344-346. doi: Copy

1.	Dong RP, Tachibana K, Hegen M, et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation 〔Ｊ〕. J Immunol, 1997; 159(12)∶6070.
2.	Tanaka T, Umeki K, Yamamato I, et al. CD26 (dipeptidyl peptidaseⅣ/DPPⅣ) as a noval molecular marker for differentiated thyroid carcinoma 〔Ｊ〕. Int J Cancer, 1995; 64(7)∶326.
3.	Eichler W, Hamann J, Aust G. Expression characteristics of the human CD97 antigen 〔Ｊ〕. Tissue Anti, 1997; 50(6)∶429.
4.	Aust G, Eichler W, Laus S, et al. CD97: a dedifferentiation marker in human thyroid carcinoma 〔Ｊ〕. Cancer Res, 1997; 57(5)∶1798.
5.	Van HKJ, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME1, CA199 and CD15 (LeuM1) in fineneedl aspirates of thyroid nodules 〔Ｊ〕. Diag Cytopathol, 1998; 18(2)∶93.
6.	Tanaka T, Umeki K, Yamamoto I, et al. Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: strong suppression of peroxidase gene expression 〔Ｊ〕. J Pathol, 1996; 179(1)∶89.
7.	Aogi K, Kitahara K, Buley I, et al. Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fineneedle aspirates 〔Ｊ〕. Clin Cancer Res, 1998; 4(8)∶1965.
8.	Klugbauer S, Demidekik EP, Lengfelder E, et al. Detection of a novel type of RET rearrangment (PTC5) in thyroid carcinoma after cherobyl and analysis of the invoved RETfused gene RFG5 〔Ｊ〕. Cancer Res, 1998; 58(2)∶198.
9.	Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinoma lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes〔J〕. Clin Cancer Res, 1998; 4(2)∶287.
10.	Uchino S, Noguchi S, Adachi M, et al. Noval point mutation and allele loss at the RET locus in sporadic medullary thyroid carcinoma 〔Ｊ〕. Jpn J Cancer Res, 1998; 89(4)∶411.
11.	Drlandi F, Saggiorato E, Pivano G, et al. Galectin3 is a presurgical marker of human thyroid carcinoma 〔Ｊ〕. Cancer Res, 1998; 58(14)∶3015.
12.	Takano T, Matsuzuka F, Miyauchi A, et al. Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study 〔Ｊ〕. Br J Cancer, 1998; 78(2)∶221.
13.	Tennings TA, Boguniewicz AB, Sheehan CE, et al. Involucrin selectively stains papillary thyroid carcinoma 〔Ｊ〕. Appl Immunohistochem, 1998; 6(2)∶55.
14.	Basolo F, Fiore L, Pollina L, et al. Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies 〔Ｊ〕. Clin Cancer Res, 1998; 4(2)∶381.
15.	SOH EY, DUN QY, SDBHI SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid 〔Ｊ〕. J Clin Endocrinol Metab, 1997; 82(12)∶3741.
16.	Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis 〔Ｊ〕. J Natl Cancer Inst, 1998; 90(4)∶273.
17.	Papotti M, Riella P, Montemurro F, et al. Immunophenotypic heterogeneity of hyalinizing trabecular tumor of the thyroid 〔Ｊ〕. Histopathology, 1997; 31(8)∶525.
18.	Lucas SD, EK B, Rosk L, et al. Aberrantly expressed cytokeratin1, a tumorassociated autoantigen in papillary thyroid carcinoma 〔Ｊ〕. Int J Cancer, 1997; 73(2)∶171.
19.	Poblete MT, Nualart F, Pozo MD, et al. Alpha1antitrypsin expression in human thyroid papillary carcinoma 〔Ｊ〕. Am J Surg Pathol, 1996; 20(8)∶956.
20.	Ragno G, Montuori N, Coralli B, et al. Differential expression of a truncated form of the urokinasetype plasminogenactivator receptor in normal and tumor thyroid cells 〔Ｊ〕. Cancer Res, 1998; 58(6)∶1315.

1. Dong RP, Tachibana K, Hegen M, et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation 〔Ｊ〕. J Immunol, 1997; 159(12)∶6070.
2. Tanaka T, Umeki K, Yamamato I, et al. CD26 (dipeptidyl peptidaseⅣ/DPPⅣ) as a noval molecular marker for differentiated thyroid carcinoma 〔Ｊ〕. Int J Cancer, 1995; 64(7)∶326.
3. Eichler W, Hamann J, Aust G. Expression characteristics of the human CD97 antigen 〔Ｊ〕. Tissue Anti, 1997; 50(6)∶429.
4. Aust G, Eichler W, Laus S, et al. CD97: a dedifferentiation marker in human thyroid carcinoma 〔Ｊ〕. Cancer Res, 1997; 57(5)∶1798.
5. Van HKJ, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME1, CA199 and CD15 (LeuM1) in fineneedl aspirates of thyroid nodules 〔Ｊ〕. Diag Cytopathol, 1998; 18(2)∶93.
6. Tanaka T, Umeki K, Yamamoto I, et al. Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: strong suppression of peroxidase gene expression 〔Ｊ〕. J Pathol, 1996; 179(1)∶89.
7. Aogi K, Kitahara K, Buley I, et al. Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fineneedle aspirates 〔Ｊ〕. Clin Cancer Res, 1998; 4(8)∶1965.
8. Klugbauer S, Demidekik EP, Lengfelder E, et al. Detection of a novel type of RET rearrangment (PTC5) in thyroid carcinoma after cherobyl and analysis of the invoved RETfused gene RFG5 〔Ｊ〕. Cancer Res, 1998; 58(2)∶198.
9. Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinoma lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes〔J〕. Clin Cancer Res, 1998; 4(2)∶287.
10. Uchino S, Noguchi S, Adachi M, et al. Noval point mutation and allele loss at the RET locus in sporadic medullary thyroid carcinoma 〔Ｊ〕. Jpn J Cancer Res, 1998; 89(4)∶411.
11. Drlandi F, Saggiorato E, Pivano G, et al. Galectin3 is a presurgical marker of human thyroid carcinoma 〔Ｊ〕. Cancer Res, 1998; 58(14)∶3015.
12. Takano T, Matsuzuka F, Miyauchi A, et al. Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study 〔Ｊ〕. Br J Cancer, 1998; 78(2)∶221.
13. Tennings TA, Boguniewicz AB, Sheehan CE, et al. Involucrin selectively stains papillary thyroid carcinoma 〔Ｊ〕. Appl Immunohistochem, 1998; 6(2)∶55.
14. Basolo F, Fiore L, Pollina L, et al. Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: in vitro and in vivo studies 〔Ｊ〕. Clin Cancer Res, 1998; 4(2)∶381.
15. SOH EY, DUN QY, SDBHI SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid 〔Ｊ〕. J Clin Endocrinol Metab, 1997; 82(12)∶3741.
16. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis 〔Ｊ〕. J Natl Cancer Inst, 1998; 90(4)∶273.
17. Papotti M, Riella P, Montemurro F, et al. Immunophenotypic heterogeneity of hyalinizing trabecular tumor of the thyroid 〔Ｊ〕. Histopathology, 1997; 31(8)∶525.
18. Lucas SD, EK B, Rosk L, et al. Aberrantly expressed cytokeratin1, a tumorassociated autoantigen in papillary thyroid carcinoma 〔Ｊ〕. Int J Cancer, 1997; 73(2)∶171.
19. Poblete MT, Nualart F, Pozo MD, et al. Alpha1antitrypsin expression in human thyroid papillary carcinoma 〔Ｊ〕. Am J Surg Pathol, 1996; 20(8)∶956.
20. Ragno G, Montuori N, Coralli B, et al. Differential expression of a truncated form of the urokinasetype plasminogenactivator receptor in normal and tumor thyroid cells 〔Ｊ〕. Cancer Res, 1998; 58(6)∶1315.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

THE ADVANCE OF MARKERS FOR THYROID NEOPLASM

Abstract Full text Figures/Tables Video References Cited by

Format

Content